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Tissue markers may be helpful in enhancing prediction of radiation therapy (RT) failure of prostate cancer (PCa). Among the
various biomarkers tested in Phase III randomized trials conducted by the Radiation Therapy Oncology Group, p16, Ki-67,
MDM2, COX-2, and PKA yielded the most robust data in predicting RT failure. Other pathways involved in RT failure are also
implicated in the development of castration-resistant PCa, including the hypersensitive androgen receptor, EGFR, VEGF-R, and
PI3K/Akt. Most of them are detectable in PCa tissue even at the time of initial diagnosis. Emerging evidence suggests that RT
failure of PCa results from a multifactorial and heterogeneous disease process. A number of tissue markers are available to identify
patients at high risk to fail RT. Some of these markers have the promise to be targeted by drugs currently available to enhance the
eﬃcacy of RT and delay disease progression.
1.Introduction
Radiation therapy (RT), including brachytherapy, external
beam radiation, and proton therapy, is one of the most
popular treatment options for clinically localized prostate
cancer. A major problem with external beam radiation of
solid tumors is the limited amount of radiation which can
be safely delivered to the target organ. For prostate cancer,
radiation doses are generally limited to <80 Gray because of
the increased risk of toxicity at higher doses and the lack of
clinical evidence that doses >80 Gray improve local tumor
control. New strategies aim to sensitize tumors to radiation
[1]. Androgen deprivation therapy (ADT) in combination
with RT has been so far the only successful sensitizing
strategy that has improved cause-speciﬁc survival in men
with locally advanced prostate cancer [2, 3].
Various genetic and epigenetic abnormalities have been
associatedwithradiation-resistantPCa(RRPCa).TheRadia-
tion Therapy Oncology Group (RTOG) can be credited with
having performed the most extensive studies of biomarkers
in men with clinically localized prostate cancer treated with
external beam radiotherapy on two phase III randomized
trials, RTOG 8610 and RTOG 9202. To date, preliminary
assessments of p53, DNA ploidy, p16/pRB, Ki-67, MDM2,
bcl-2/bax, and CAG repeats, COX-2, Stat3, Cyp3A4, and
protein kinase A (PKA) have been completed [4]. It is
noteworthy that most of these tissue markers are not speciﬁc
for RT failure and may have also prognostic implications in
PCa patients treated with surgery and androgen deprivation.
The present review is focused on pathways implicated in
RT failure of PCa to deﬁne etiological factors which can be
targeted by drugs currently available to enhance the eﬃcacy
of RT and delay disease progression.
2. Anatomic FactorsImplicatedin
Radiotherapy Failure
PCa cells located at the limit of and outside the radiation
ﬁeld will fail RT. Perineural invasion is a common pathway
by which PCa cells transverse the prostate capsule to reach
the extraprostatic tissue. Clinical studies have identiﬁed per-
ineural invasion present in prostate biopsy an independent
risk factor for recurrence and cause-speciﬁc death after RT
[5, 6].
Lymphatic invasion is the ﬁrst step to lymphatic spread
and lymph node metastasis (Figure 1(a)). In prostatectomy
specimens, the presence of lymphatic invasion detected by2 Prostate Cancer
(a) (b)
Figure 1: Lymphovascular invasion is detected by the endothelial marker D2-40 in a prostatectomy specimen (a). Androgen receptor (AR)
immunohistochemistry detects disseminated prostate cancer cells in lymph nodes classiﬁed as negative for cancer upon routine histological
examination. Original magniﬁcations: a (×400), b (×300).
the endothelial marker D2-40 is a major risk factor of lymph
nodemetastasisatthetimeofprostatectomy,anindependent
risk factor for PSA recurrence and cancer death in patients
treated with prostatectomy, and an independent risk factor
for disease recurrence after salvage RT [7–11].
Disseminated tumor cells (occult metastases) are de-
tectable by immunohistochemical markers (keratins, PSA,
androgen receptor) in lymph nodes qualiﬁed as negative
(pN0) upon histological examination (Figure 1(b)). In a
recent study of 180 patients with pathological stage pT3,
pN0, occult lymph node metastases (OLN+) were found in
13.3%. The presence of OLN+ was signiﬁcantly associated
with increased recurrence and decreased survival compared
with OLN negative patients (P<0.001 and P = 0.019,
resp., relative risk of recurrence, 2.27; relative risk of death
2.07, resp.). The presence of occult lymph node metastases
was an independent predictor of recurrence and death in a
multivariable analysis. The outcome for patients with OLN+
disease was similar to that for patients with histological
evidence of lymph node metastases (pN1) [12]. Hence, the
presence of disseminated tumor cells (occult metastases) in
lymphnodesqualiﬁedasnegative(pN0)isnotarareeventin
pT3, pN0 disease, and is an important risk factor of therapy
failure after salvage RT.
It is noteworthy that neither lymphatic invasion (pL1)
nor disseminated tumor cells in lymph nodes (OLN+) are
considered in current nomograms, and thus escape clinical
risk evaluation.
3. PathwaysImplicatedinRadiotherapyFailure
MajorpathwaysimplicatedinRTfailureinsolidtumorsrefer
to tumor cell proliferation, resistance to apoptotic cell death,
aberrant growth factor receptor expression, and hypoxia.
In PCa, the ﬁrst three pathways are closely entangled to
androgen receptor (AR) signaling, which plays a pivotal
role in progression to castration-resistant PCa (CRPCa).
In this review we adapt current models proposed for the
pathogenesis of CRPCa [13–16] to discuss basic mechanisms
involved in RRPCa. Current pathogenetic concepts implicate
CRPCa a multifactorial and heterogeneous disease process
involving several pathways [13–23] including the following.
(a) UpregulationofARexpressioninPCacellsmaintain-
ingARsignalingunderstandardADT(hypersensitive
pathway).
(b) Enhanced ligand-dependent activation of the AR by
increase of intratumoral de novo synthesis of testos-
terone and dihydrotestosterone (DHT).
(c) Ligand-independent activation of the AR by non-
hormonal growth factor receptors (erb1/EGFR,
erb2/HER2, etc.; outlaw pathway).
(d) Broadened ligand speciﬁcity of AR mutants binding
nonandrogen steroids (estrogens, progestins, etc.;
promiscuous pathway).
(e) AR-independent mechanisms (bcl-2, neuroendo-
crine (NE) diﬀerentiation, etc.) maintaining survival
and growth by bypassing the AR (bypass pathway).
(f) Continuous resupply of tumor cell populations
under ADT by prostate cancer stem cell regeneration
(stem cell pathway).
As it will be discussed in the following sections, most of
these pathways (a, b, c, e, and f) are also relevant for the
development of RRPCa. AR mutations (d) mainly occur in
metastatic lesions and are unlikely to play a major role in RT
failure of PCa.Prostate Cancer 3
3.1. Hypersensitive Pathway. The AR governs vital functions
of PCa cells, such as proliferation and survival, and is
therefore involved in the biology of RRPCa. Experimental
data have convincingly demonstrated that upregulation of
the AR at the mRNA and protein level is suﬃcient to convert
castration-sensitive to castration-resistant PCa growth. This
hypersensitive pathway has been recognized as a major
determinant for the development of CRPCa by maintaining
AR signaling during standard ADT [19]. High level of AR
expression has been documented by immunohistochem-
istry not only in CRPCa, but also in hormone-na¨ ıve PCa
(Figure 2(a)).Severalclinicalstudiesperformedinhormone-
na¨ ıve PCa obtained from prostatectomy specimens have
shown that high levels of AR expression correlate with
the Gleason grade, pathological stage, lymph node status,
and PSA recurrence, suggesting that PCa expressing the
AR at high levels behave clinically more aggressively than
tumors without AR upregulation [24–28]. Since ADT in
combination with RT has been demonstrated to improve
cause-speciﬁc survival [2, 3], it is likely that the AR status in
PCa tissue may predict the outcome of patients treated with
radiation. Recent data indicate that increased AR expression
in PCa detected in biopsy specimens signiﬁcantly predicts
resistance to therapy, that is ADT with or without salvage
radiotherapy, and any clinical failure [28]. Nevertheless,
further studies are required to determine the signiﬁcance of
the AR status in PCa tissue for predicting RT failure.
Unopposed tumor cells proliferation under ADT is one
of the hallmarks of CRPCa, but is also relevant in the devel-
opment of RRPCa. In the RTOG 8610 and the subsequent
RTOG 9202 trail, the proliferation-associated Ki-67 (MIB-
1) labeling index ≤3.5% and >3.5%, was associated with
the risk of distant metastasis (P<0.0001), disease speciﬁc
survival (P<0.0001), and overall survival (P<0.01), and
was the most signiﬁcant predictor of the ﬁrst two endpoints
[4]( Figure 2(b)). It is not surprising that some of the key
regulators of the cell cycle in PCa cells (i.e., PTEN (phos-
phataseandtensinhomologue),p27,andp16)areimplicated
in RT failure. When PTEN is lost on chromosome 10
(which occurs in more than 20% of PCa with Gleason ≥7),
the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian
target of rapamycin (mTOR) pathway is activated leading
to phosphorylation of the AR (→ hypersensitive AR), and
increase of cell proliferation by downregulating p27 [17]. In
fact, p27 prevents PCa cells from entry into the cell cycle and
functions as tumor suppressor. Loss of p27 in PCa demon-
strated by immunohistochemistry has prognostic implica-
tions (reviewed by Quinn et al. [29]). In castration-sensitive
PCa, ADT increases p27 expression which, in turn, prevents
PCa cells from proliferation. In CRPCa, p27 is lost, implicat-
ing that tumor cells continue to proliferate under ADT. Low
expression of p27 in salvage prostatectomy specimens have
been reported a signiﬁcant predictor of survival for patients
with recurrent disease after RT [30]. In the radioresistant
PCa cell lines PC-3 and DU-145, PTEN is deleted and
the PI3K/AKT pathway suppressed. Restoration of PTEN
sensitizes these cells to the killing eﬀect of radiation [1].
p16 is another important regulator of the cell cycle at the
G(1) phase. In the RTOG 8610 trail, loss of p16 expression
was associated with an increased risk of local failure, distant
metastasis, and disease-speciﬁc survival (P<0.01; P<0.03;
and P<0.01, resp.) and there was a borderline association
with overall survival (P = 0.07) [4]. In the subsequent
RTOG 9202 study enrolling 612 patients, reduced expression
was associated with an increased rate of distant metastases
(P<0.04). Among patients with high expression of p16,
the use of long-term ADT was associated with an increase in
cause-speciﬁc survival and a decreased incidence of distant
metastasis compared to short-term ADT, suggesting that
patientswithhighp16expressionrequirelongtermADT[4].
The protein kinase A type 1 (PKARIα)) belongs to a
family of cyclic AMP-dependent enzymes that are involved
in the hypersensitive pathway by regulating both the level of
AR expression and cell proliferation. Preclinical data indicate
that PKARIα knockdown with antisense oligonucleotides
signiﬁcantly inhibits PCa cell growth in vitro and in vivo
when combined with ADT and RT, and downregulates
expression of the AR (AR silencing) [31]. In the RTOG 8610
and the subsequent RTOG 9202 trail, staining intensities
wereindependentpredictorsofdistantmetastasis(P<0.01),
local failure (P<0.05), and biochemical failure (P ≤ 0.01).
Furthermore, the beneﬁt of long-term ADT over short-term
ADT was much less when PKARIα expression was high [32].
Cumulatively, the current data suggest that high prolifer-
ation activity associated with deregulated cell cycle control
(hypersensitive AR, PTEN/PI3K/Akt, p16, and PKA) are
involved in RT failure in PCa.
3.2. Outlaw Pathway. PCa cells can maintain AR signaling,
proliferation, and survival in an androgen-deprived milieu
through activation of nonsteroidal growth factor recep-
tors, including vascular endothelial growth factor receptor
(VEGFR), insulin-like growth factor receptor (IGFR), ker-
atinocyte growth factor receptor (KGFR), epidermal growth
factor receptor (EGFR), transforming growth factor receptor
β (TGF β-R), and interleukine-6 receptor (IL6-R). Phospho-
rylation of the AR by growth factors and their receptors
requires mitogen-activated protein kinases (MAPK) and
PI3K/AKT/mTOR downstream kinase signaling [13–18, 20,
22].Thesenonsteroidalreceptor-relatedoutlawpathwaysnot
only maintain and increase AR signaling (→ hypersensitive
pathway), but are also involved in RT failure through various
mechanisms.
Activation of EGFR family members (erb1/EGFR, erb2/
HER2, erb3/HER3, and erb4/HER4) via the PI3K/Akt/
mTORpathwayisimplicatedinradioresistancebyregulating
hypoxia-inducible factor 1α (HIF-1α) and vascular endothe-
lial growth factor (VEGF) expression, a potent mediator
of angiogenesis (reviewed by Karar and Maity, [33]). In
addition, radiation can enhance EGFR expression, which,
in turn, increases radioresistance of cancer cells. In PCa,
upregulation of EGFRs (such as erb1/EGFR, erb2/HER2) are
mainly encountered in tumors with high Gleason grades and
predictpooroutcome[29](Figure 3(a)).DetectionofEGFRs
at high levels in the patient’s PCa tissue may be a signiﬁcant
riskfactorofRTfailure,butthishasnotyetbeeninvestigated.4 Prostate Cancer
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Figure 2: Androgen receptor (AR) status in hormone- and radio- na¨ ıve PCa, Gleason 3+4 = 7( Figure 2(a)). The AR is expressed at higher
levels when compared with adjacent benign acini (arrows), indicating a hypersensitive pathway. Proliferation activity usually correlates with
the Gleason grade. Figure 2(b) shows an example of a PCa, Gleason 3 + 3 = 6, with relatively high proliferation activity (MIB-1 index >
10%), which implies a higher risk of RT failure than the Gleason grade would suggest. Original magniﬁcations: (a) (×300), (b) (×400).
(a) (b)
Figure 3: Hormone- and radio-na¨ ıve PCa (Gleason 4 + 4 = 8) with strong membraneous HER2/neu expression (Figure 3(a)), indicating
that the outlaw pathway is relevant for tumor progression under standard ADT and RT. Local PCa recurrence after salvage radiotherapy
(Figure 3(b)). High levels of bcl-2 expression indicate that standard ADT is insuﬃcient for local tumor control. Since docetaxel inhibits the
antiapoptotic function of bcl-2, ADT combined with docetaxel may be more successful for local tumor control than standard ADT alone.
Original magniﬁcations: (a) (×400), (b) (×100).
Hypoxia and acidiﬁcation caused by increased glycolysis
and CO2 production are other signiﬁcant determinants in
RT failure (reviewed by Karar and Maity, [33]). The acidic
and hypoxic microenvironment can make cells resistant to
both radiation and chemotherapy. Hypoxic cells require
higher doses of radiation compared to oxic cells to achieve
the same cytotoxic eﬀect. In fact, oxygen present during
radiation exposure is critical to elicit maximal DNA damage
through the creation of free radicals [33]. The hypoxic
microenvironment upregulates not only the expression of
HIF-1 and VEGF (via the PI3K/Akt/mTOR pathway), but
also induce the transcription factors nuclear factor-kappa
B( N F - κB) and signal transducers and activators of tran-
scription 3 (Stat3), which are constitutively active in most
cancers, including PCa. NF-κB regulates AR expression and
various other pathways implicating in inﬂammation (IL-
6, IL-8, COX-2), cell survival (BCL-2), cell proliferation
(cyclin D1, c-myc), invasion, angiogenesis (VEGF, FGF), andProstate Cancer 5
metastasis (reviewed by Aggarwal et al., [34]). Increased NF-
κB expression levels are associated with PCa progression and
the development towards castration-resistant disease [35,
36].Interestingly, NF-κBisr egulat edbythePTEN/PI3K/AKT
pathway. The signiﬁcance of NF-κB expression in human
PCa tissue for prediction of RT failure has not yet been
investigated.
Recent data suggest that Stat3 is involved in prostate
cancer metastases. Stat3 is constitutively active in 77% of
lymphnodeand67%ofbonemetastasesofclinicalPCa[37].
Stat3 expression was evaluated in a subset of 62 patients who
had suﬃcient tissue from RTOG 8610 [4]. Activated Stat3
was inversely correlated with the development of distant
metastasis (P = 0.04), but not survival or local control,
although due to the small sample size this conclusion has to
be interpreted with caution [4].
In summary, a number of biomarkers implicated in the
outlaw pathway of CRPCa are potential targets for radiosen-
sitization, including erb1/EGFR, erb2/HER2, erb3/HER3,
PTEN/PI3K/AKT, HIF-1, VEGF-R, NF-κB, and Stat3.
3.3. Bypass Pathway. Several mechanisms have been recog-
nizedofhowPCacellssurviveADTbybypassingtheAR.The
bypass pathway mainly refers to the programmed cell death,
which is a major molecular determinant of radioresponse.
Bcl-2 is a mitochondrial protein conferring resistance
to programmed cell death. The basal cell layer which
harbors the stem cell and proliferation compartment of the
prostatic epithelium uniformly expresses bcl-2 conferring
basal cells resistance to various apoptotic conditions. In
fact, basal cells are particularly resistant to radiation and
other cytotoxic agents such as ADT and chemotherapy. In
PCa, overexpression of bcl-2 is related to high grades and
advanced stages, and is considered a prognostic marker
for poor outcome and resistance to ADT (reviewed by
Quinn et al. [29]( Figure 3(b)). Bcl-2 expression may also
be induced or increased by ADT and RT (Figure 4(b)). In
a study including 20 radio-na¨ ıve and 20 radio-recurrent
PCa, all radio-na¨ ıve tumors were bcl-2 negative while 55%
of the radio-recurrent tumors were bcl-2 immunopositive
[38]. Bcl-2 and the proapoptotic bcl-2 family member Bax
were evaluated in the RTOG 8610 study, but both were not
related to outcomes. In the follow-up RTOG 9202 study,
the combination of negative bcl-2/normal bax expression
was related to reduced biochemical failure (P = 0.036),
particularly among those who received short-term ADT
suggestingthatlong-termADTmightbeadvisedwheneither
bcl-2 or Bax is abnormally expressed [4].
Neuroendocrine (NE) diﬀerentiation frequently occurs
in common PCa but usually escapes histological and clinical
detection [39–41]. NE tumor cells do not secrete PSA and
become detectable in PCa tissue only upon immunohisto-
chemical analysis. About 10% of PCa (mainly poorly diﬀer-
entiated tumors) show signiﬁcant (extensive and multifocal)
NE diﬀerentiation with the NE marker chromogranin A
(CGA) [39]( Figure 4(a)). NE PCa cells consistently lack the
AR and present an androgen-insensitive phenotype in all
stages of the disease [40, 41]. NE diﬀerentiation exclusively
occurs in the G0-phase of the cell cycle, in which tumor cells
are particularly resistant towards cytotoxic conditions such
as RT and chemotherapy [40, 41]. Although NE PCa cells
do not proliferate, they produce a number of NE growth
factors, including serotonin and bombesin that trigger cell
proliferation of adjacent exocrine tumor cells through a
paracrine mechanism [40, 41]. They also regulate angiogen-
esis by secreting VEGF. Most strikingly, NE PCa cells escape
programmed cell death and represent a potential immortal
tumor cell population in PCa [42]. The stem cell marker
CD44 is expressed in PCa selectively in NE tumor cells, indi-
cating that these cells are endowed with stem cell properties
[43]. Given its multidrug-resistant nature, it is not surprising
thatNEdiﬀerentiationmaysigniﬁcantlyincreaseunderADT
and RT. Pretreatment-elevated serum NSE (neuron-speciﬁc
enolase), but not initial CgA, has been associated with an
unfavorableprognosisinpatientstreatedwithRT[44,45].In
short, NE diﬀerentiation characterizes a multidrug-resistant
phenotype in common PCa, and may be signiﬁcant in at
least 10% of PCa patients. Unfortunately, NE diﬀerentiation
usually escapes clinical detection and attention.
COX-2 (cyclooxygenase-2) is a proinﬂammatory enzyme
that converts arachidonic acid to prostaglandins, particu-
larly PGE2. Inﬂammatory processes are implicated in PCa
development and tumor progression. During tumor pro-
gression, the androgen-sensitive prostatic stroma is replaced
by an androgen-insensitive tumor stroma, in which factors
such as hypoxia, acidosis and inﬂammation promote the
release of growth factors implicated in outlaw pathways,
and upregulation of COX-2 in PCa cells [14, 34]. In these
inﬂammatory tumor-microenvironment interactions, COX-
2 and PGE2 play a key role. Inhibition of the COX-2
pathway downregulates a number of important targets of
CRPCa,includingAR,EGF-R,AKT,andcyclinD[46].Other
preclinical data have shown that COX-2 overexpression and
subsequently targeting COX-2 with COX-2 inhibitors may
render cells susceptible to the killing eﬀects of radiation
(reviewed by Rosser et al. [1] ) .S i m i l a rt ow h a tw a sr e p o r t e d
for bcl-2, cancer cells exposed to low doses of radiation up-
regulate COX-2 expression as a possible means to survive
the radiation exposure [1]. Results of the RTOG 9202 study
have identiﬁed COX-2 an independent marker for therapy
failure after external radiation. In multivariate analyses, the
intensity of COX-2 staining was an independent predictor
of distant metastasis, biochemical failure, and any failure
[47]. Hence, COX-2 oﬀers a relevant therapeutic target in
PCa’s patients treated with radiation, provided that COX-2
is present in the patient’s PCa tissue.
p53 functions by regulating the transcription of genes
involved in G1-phase growth arrest and apoptosis in
response to DNA damage. Frequently mutated and upreg-
ulated in high-grade and metastatic disease, abnormal
accumulation of p53 in PCa tissue have been associated with
PCa progression and poor outcomes [29]. In the RTOG 8610
and 9202 studies, abnormal p53 expression was signiﬁcantly
associated with risk of distant metastasis and cause-speciﬁc
survival [4].
MDM2 acts as an oncoprotein promoting p53 degra-
dation. A recent study has combined MDM2 with MIB-16 Prostate Cancer
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Figure 4: Conventional PCa (Gleason 4 + 4 = 8) detected in a needle biopsy. Chromogranin A (CGA) immunohistochemistry reveals
extensiveneuroendocrine(NE)diﬀerentiation,whichpresentsamultidrug-resistantphenotypeinPCa(a).Immunohistochemical detection
of somatostatin receptors in NE PCa cells (b) provides a therapeutic target for somatostatin analogues. Original magniﬁcations: (a) (×100),
(b) (×300).
(Ki-67) in 478 patients treated on RTOG 9202. The results
indicate that combined MDM2 and MIB-1 expression levels
areindependentlyrelatedtodistantmetastasisandmortality,
andispromisinginidentifyingmenataparticularlyhighrisk
of distant metastases [48]. Experimental data indicate that
antisense-MDM2 sensitizes LNCaP prostate cancer cells to
androgen deprivation and radiation [49].
3.4. Stem Cell Pathway. Some pathogenetic factors impli-
cated in progression towards CRPCa and RRPCa are also
required for survival and growth of the normal prostatic
epithelium exposed to ADT, RT, and other cytotoxic con-
ditions. The cellular integrity of the prostatic epithelium is
maintained by basal cells which are particularly resistant to
ADT, chemotherapy, and radiation. Basal cells, in appar-
ent contrast to secretory luminal cells, are endowed with
multidrug resistance properties. The basal cell layer of the
prostatic epithelium is androgen-independent and harbors
the proliferation and the stem cell compartment of the
prostatic epithelium [50]. Bcl-2, involved in bypass pathways
of CRPCa, and RRPCa, is the major antiapoptotic protein
protecting basal cells from programmed cell death. Non-
hormonal growth factor receptors (erb1/EGFR, erb2/HER2,
etc.) responsible for outlaw pathways implicated in CRPCa
and RRPCa are selectively expressed in the basal cell layer
[50]. Hence, basal cells, RRPCa and CRPCa cells share
common multidrug resistance pathways. The progressive
emergence of basal cell speciﬁc pathways (including bcl-
2, erb1/EGFR, erb2/HER2) during progression towards
CRPCa and RRPCa phenotypes suggests that these tumors
recapitulate biological properties of basal cells and stem cells
to acquire multidrug resistance.
The basal cell layer of the prostatic epithelium harbors
a small stem cell population (<1%) which expresses CD44,
α2β1 integrin and CD133 [51] .T h es a m em a r k e rp r o ﬁ l eh a s
been identiﬁed in about 0.1% of tumor cells of any PCa.
These very rare tumor cells possess a signiﬁcant capacity
for self-renewal and most likely represent prostate cancer
stem cells [52]. PCa stem cells are considered multidrug-
resistant tumor cells that continually resupply tumor cells
under ADT, RT and others cytotoxic conditions, and may be
responsible for therapy failure. It has been shown recently
that most lethal metastatic PCa arise from a single precursor
cancercell,andthatPCastemcellsareabletogeneratehighly
tumorigeniccellpopulations[51].Detectionofputativestem
cell markers in PCa specimens by immunohistochemistry
may become important in the near future to select patients
for targeting the stem cell pathway.
4. Potential Therapeutic Targets for
Radiosensitization of Prostate Cancer
Disease relapse after deﬁnitive RT is usually identiﬁed by
elevated or rising serum PSA proﬁles during and after treat-
ment. Nevertheless, relevant pathogenetic factors implicated
in the development of RRPCa are detectable in radio-na¨ ıve
PCa long before the clinical onset of the disease. This
includes pathways related to AR, PTEN/PI3K/AKT, EGFR’s,
VEGFR, NF-κB/stat3, bcl-2, COX-2, and CGA. Although
these pathways and related tissue markers are not speciﬁc for
radioresistance, RT may induce and enhance relevant patho-
genetic factors involved in RT failure, including upregulation
of HER1, bcl-2, CGA, COX-2, and NF-κB/stat3.
The following predictive markers are promising to
identify PCa patients at high risk to fail RT and to provideProstate Cancer 7
Table 1: Selection of potential markers/targets and pathways implicated in the development of radioresistant prostate cancer, their
signiﬁcance in predicting radiation therapy (RT) failure, and potential therapeutic inventions/agents.
Marker/target Pathway Prediction of RT failure Potential therapeutic inventions/agents
D2-40 Metastatic ‡ (7–11) Pelvic radiation
OLN+ Metastatic ‡ (12) Pelvic radiation
AR Hypersensitive ‡ (28) AR silencing, MDV3100 [53]
Statins [54, 55], abiraterone [56]
PKA Hypersensitive ‡ (4), (32) AR silencing, PKA knockdown [31]
Ki-67/MDM2 Proliferation ‡ (48) AR silencing, antisense-MDM2 [49]
p16 Proliferation ‡ (4) AR silencing
erb1/EGFR (HER-1) Outlaw NYD
Geﬁtinib [15, 57]
Erlotinib [58]
PI3K/AKT/mTOR inhibitors [59]
HSP-90 inhibitors [60]
erb2/HER2 (HER-2/neu) Outlaw NYD
Pertuzumab
PI3K/AKT/mTOR inhibitors [59]
HSP-90 inhibitors [60]
VEGF-R Outlaw NYD Bevacizumab, aﬂibercept, sunitinib [23]
PI3K/AKT/mTOR Outlaw NYD PI3K/AKT/mTOR inhibitors [59]
HSP-90 inhibitors [60]
NF-κB/Stat3 Bypass ± (4) Curcumin [34]
Bcl-2 Bypass ± (4) Docetaxel [61] AT-101 [23]
Clusterin Bypass ± OGX-001 [16]
COX-2 Bypass ‡ (47) Celecoxib, etoricoxib [62–64]
CGA (somatostatin
receptor) Bypass NYD Lanreotide [65–67]
CD44/CD133 Stem cell NYD PI3K/mTOR inhibitor NVP-BEZ235 [68]
CD44/CD133 Stem cell NYD Gamma-tocotrienols [69]
OLN+: occult lymph node metastasis; AR: androgen receptor; PKA: protein kinase A; EGFR: epithelial growth factor receptor; VEGF-R: vascular endothelial
growth factor receptor; PI3K/AKT/mTOR: phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin; NF-κB/Stat3: transcription factors
nuclear factor-kappa B (NF-κB) and signal transducers and activators of transcription 3 (Stat3), COX-2: cyclooxygenase 2; CGA: chromogranin A;
‡: signiﬁcant prediction of RT failure has been reported.
±: signiﬁcant prediction of RT failure has not been reported.
NYD: not yet determined.
therapeutic targets for radiosensitization to slow disease
progression (Table 1).
4.1. Targeting Disseminated Tumor Cells. Detection of peri-
tumoral lymphatic invasion (pL1) and occult lymph node
metastasis (OLN+) by immunohistochemistry in lymph
nodes reported as negative for cancer are signiﬁcant risk
factors for tumor recurrence after salvage radiation therapy
[11, 12]. In patients with PSA recurrence after prostatectomy
and clear evidence of pL1 or OLN+, extension of the
radiation ﬁeld to the pelvic lymphatic drainage may improve
clinical outcome (Figure 1).
4.2. Targeting the Hypersensitive Pathway. Determination of
the AR status by immunohistochemistry provides a powerful
tool for predicting therapy failure after prostatectomy and
response to ADT with or without salvage radiotherapy [28].
Detection of high level expression of AR in hormone- and
radio-na¨ ıve PCa cells implicates the hypersensitive pathway
as relevant for the individual disease process (Figure 2(a)).
In this case, a standard ADT is not suﬃcient, because
hypersensitive ARs use androgens at castration levels.
AR silencing by downregulating AR expression is a new
approach for targeting the hypersensitive pathway [14, 17,
21, 22]. Experimental data using synthetic small interference
RNA and AR antisense oligonucleotides have shown that
downregulation of AR expression is suﬃcient to slow tumor
growth and to induce apoptosis. A new class of selective AR
modulators (SARMs) targeting the hypersensitive pathway
has been described recently. Nonsteroidal antiandrogens
diarylthiohydantoins RD162 and MDV3100 bind to AR with
greater aﬃnity than the classical antiandrogen bicalutamide,
reduce nuclear translocation of the AR (AR silencing), and
impair both DNA binding to androgen response elements
and recruitment of coactivators [53]. Both SARMs (RD162
and MDV3100) are orally available and induce tumor
regression in mouse CRPCa models. A clinical phase I/II
trial with MDV3100 enrolling 140 patients with CRPCa has
shown sustained declines (by>50%) in serum PSA in 56% of8 Prostate Cancer
patients, responses in soft tissue in 13 (22%) of 59 patients,
stabilized bone disease in 61 (56%) of 109 patients, and
conversion from unfavorable to favorable circulating tumor
cellcountsin25(49%)ofthe51patients.Themediantimeto
progression was 47 weeks for radiological progression [53].
It is conceivable that these SARMs (RD162 and MDV3100)
targeting the hypersensitive pathway may also be eﬀective to
slow disease progression in patients at high risk to fail RT,
and documented high level of AR expression in PCa tissue at
the time of the initial diagnosis. Finally, natural agents, such
as vitamin D3 and E, selenium, phytoestrogens, resveratrol,
pomegranate fruit extract, and silymarin, have AR silencing
activity documented in various PCa cell lines, [17, 21].
The hypersensitive pathway is further boosted by the
increase of intratumoral testosterone synthesis. In fact,
PCa uses cholesterol for intratumoral de novo testosterone
synthesis, which is markedly increased in metastatic and
CR disease [56]. Cholesterol lowering by statin use during
high-dose RT for clinically localized prostate cancer has been
reported to be associated with a signiﬁcant improvement
in freedom from biochemical failure, freedom from salvage
androgen deprivation therapy, and relapse-free survival in
high-risk patients, suggesting that statins have anticancer
activity and possibly provide radiosensitization whenused in
conjunction with RT [54, 55]. The conversion of cholesterol
to testosterone requires activity of the P450 aromatase
enzyme (CYP17 gene) which can be blocked by abiraterone
acetate [23, 56]. The use of abiraterone acetate may also
prevent or delay RT failure in patients with high level of AR
expression in their PCa tissue.
4.3. Targeting the Outlaw Pathway. Major growth factor
receptors implicated in the development of RRPCa, includ-
ing the EGFR family (erb1/EGFR, erb2/HER2, etc.) and
VEGFR,requirePI3K/AKT/mTORdownstreamkinasepath-
ways. This makes PI3K/AKT/mTOR signaling a promising
target for radiosensitization [1, 59]. A number of PI3K
inhibitors, including XL147 (Exelixis), BEZ235 (Novar-
tis), GDC-0941 (Genentech)), and small-molecule AKT
inhibitors (MK2206 (Merck, Inc.)) are currently in Phase 1
clinical trails (reviewed by Sarker et al., [59]). Preliminary
results with mTOR inhibitors, such as rapamycin analogs
(temsirolimus, everolimus) that inhibit the mTORC1 have
been disappointing when these analogs have been admin-
istered as single agents in CRPC. Preliminary data on dual
PI3K and mTOR inhibitors such as XL765 have recently
been presented and encouragingly show no signiﬁcant
toxicity concerns and evidence of pharmacodynamic mod-
ulation [59]. The clinical success of agents targeting the
PI3K/AKT/mTOR pathway could be maximized by prospec-
tivelyidentifyingpatientsharboringmolecularabnormalities
in this pathway who may have a higher likelihood of
responding, that is loss of PTEN demonstrated by FISH,
high levels of AKT expression, and loss of p27 identiﬁed by
immunohistochemistry in the patient’s PCa tissue.
PI3K/AKT/mTOR downstream kinase pathways also
regulate NF-κB which, in turn, regulates AR expression and
various other pathways implicated in cell survival, prolifer-
ation, invasion, angiogenesis, and metastasis (reviewed by
Aggarwal et al., [34]). Numerous agents identiﬁed from
natural sources can block the NF-κB pathway, including
curcumin, resveratrol, ursolic acid, capsaicin, silymarin,
guggulsterone, and plumbagin [34]. In human clinical trials,
curcumin has been shown to downregulate both the NF-κB
and Stat3 pathways [34].
Radiation can increase the expression of EGFR, which
has been implicated in increasing the radiation resistance
of cancer cells. A number of EGFR inhibitors including
the monoclonal antibodies cetuximab (Erbitux) and pan-
itumumab (Vectoibix) and small molecule tyrosine kinase
inhibitors geﬁtinib (Iressa) and erlotinib (Tarceva) have
shown potential in the treatment of several types of human
cancers (reviewed by Karar and Maity, [33]). In a landmark
randomized Phase III trial, treatment of locoregionally
advanced head and neck cancer with concomitant high-dose
radiotherapy plus cetuximab improves locoregional control
and reduces mortality without increasing the common toxic
eﬀects associated with radiotherapy to the head and neck
[70]. A recent Phase I/II trail of geﬁtinib combined with RT
in patients with nonmetastatic PCa has shown promising
clinical activity compared favorably with those of matched
patients treated with radiation only at higher doses [57].
Erlotinib, another tyrosine kinase inhibitor targeting EGF-
R, has shown moderate activity in chemotherapy-na¨ ıve
CRPPCa,with11%ofpatientsmeetingthecriteriaforpartial
response and 4% of patients demonstrating stable disease
[58].TheVEGFpathwayistargetedincurrentphaseIIItrials
enrollingpatientswithCRPCawithvariousagents,including
bevacizumab, aﬂibercept, and sunitinib [23]. It is clear that
tyrosine kinase inhibitors may be eﬀective only in patients
with tumors expressing pertinent growth factor receptors at
signiﬁcant level. With respect to the heterogeneous nature
of PCa, determination of the erb1/EGFR, erb2/HER2, and
VEGF-R status in PCa tissue would be the ﬁrst step towards
a better identiﬁcation and selection of patients who will
experience maximal beneﬁt from each particular tyrosine
kinase inhibitor (Figure 3(a)).
Another multitarget approach to radiosensitization is
provided by HSP-90 inhibitors. HSP-90 is a heat shock
protein which stabilizes and prevents a number of relevant
targets of CRPCa and RRPCa from degradation, including
AR, HER-1, HER-2, and AKT. Inhibition of HSP-90 function
by geldanamycin analogue results in degradation of these
client molecules and impairs their biological functions
[14, 17, 21, 22]. The geldanamycin analogues 17AAG and
17DMAG were shown to enhance the in vivo radiosensitivity
of a prostate tumor xenograft model. The geldanamycin
analogue 17-AAC was tested in a phase II trial in patients
with CRPCa, but minimal clinical activity was recorded
[23]. It is known that the HSP-90 inhibitor-induced tumor
cell radiosensitization is closely related to the EGFR status
(reviewed by Camphausen and Toﬁlon, [60]). In tumor
cells expressing erbB3, erbB1 signaling was maintained
in response to Hsp-90 inhibition and radiosensitization
was not induced. With respect to the potential design ofProstate Cancer 9
clinical protocols combining HSP-90 inhibitor and RT, the
preclinical results suggest that patients with tumors which
do not express erbB3 would be predicted to respond best to
this combined modality and that the probability of HSP-90
inhibitor-inducedradiosensitizationmaybeenhancedbythe
combined use of erbB1 inhibitors [60].
4.4. Targeting the Bypass Pathway. Targeting the bcl-2
molecule-microtubule complex with docetaxel has let to the
ﬁrst shown survival beneﬁt for patients with CRPCa [14].
Clinical studies have documented that bcl-2 positive PCa
respond better to docetaxel than bcl-2 negative tumors [61].
Knowing that ADT and RT may induce and enhance bcl-
2, determination of the bcl-2 status may be important in
recurring PCa after RT (Figure 3(b)). In tumors expressing
bcl-2 at signiﬁcant levels, combination of ADT with low-
dose docetaxel may be more eﬀective than standard ADT
alone (Figure 4(b)). In addition, bcl-2-positive PCa could
be targeted by AT-101, which is a small-molecule inhibitor
of multiple bcl-2 family members. Based on the promising
results obtained in a single-agent Phase II trial, AT-101 is
currently tested in a Phase II trial in patients with metastatic
CRPCa treated with docetaxel [23]. When clinical activity is
proven in this disease setting, AT-101 may become a promis-
ingagentforhormone-andradio-na¨ ıvePCaexpressingbcl-2
at high level.
Clusterin is a cytoprotective chaperone that inhibits
apoptosis and activates the PI3K/AKT kinase pathway
implicated in the outlaw pathway [71]. In contrast to bcl-2,
clusterin has no prognostic signiﬁcance in hormone-na¨ ıve
PCa, but is signiﬁcantly upregulated under ADT [72].
OGX-011 is a clusterin silencing antisense oligonucleotide,
which has shown promising clinical activity in patients with
CRPCa treated with chemotherapy [23]. Clusterin silencing
byOGX-011mayalsobeeﬀectivetoslowdiseaseprogression
in patients under ADT and RT. In fact, inhibition of clusterin
by antisense oligonucleotides sensitizes LNCaP cells and
PC-3 cells to RT [73].
Detection of signiﬁcant NE diﬀerentiation in PCa
(Figure 4(a)) has several implications for the patient’s care
[16, 74]. It is clear that radical prostatectomy eliminates
the multidrug-resistant NE phenotype safer than RT or
ADT. Knowing that NE PCa cells do not produce PSA, NE
serum markers like CGA and neuron-speciﬁc enolase (NSE)
may be more informative than PSA. It is well established
that NE diﬀerentiation can be induced and enhanced by
ADT. Clinical studies investigating CGA velocity under ADT
indicate that castration therapy is signiﬁcantly more eﬀective
in inducing the NE pathwaythan bicalutamide monotherapy
[75]. Intermittent ADT signiﬁcantly decreases CGA serum
levels when compared to continuous ADT, indicating that
intermittent ADT is safer than permanent ADT in PCa with
signiﬁcant NE diﬀerentiation [76]. It is noteworthy that
NE diﬀerentiation is activated via interleukin 6 (IL-6) and
PI3K/Akt/mTOR signaling, which could be targeted accord-
ingly [77]. Another important target for this multidrug-
resistant phenotype is the somatostatin receptor. In fact, NE
PCa cells may express somatostatin receptors, which can be
targeted by somatostatin analogues (Figure 4(b)). Objective
clinical response and marked decrease of serum CGA have
beenreportedinpatientswithCRPCatreatedwithlanreotide
in combination with dexamethasone or ethinylestradiol [65–
67]. Hence, evaluation of the somatostatin receptor status in
PCa tissue may be important for targeting the NE phenotype
with somatostatin analogues.
Increased COX-2 expression in PCa tissue is considered
an independent risk factor for RT failure [47]. Preliminary
clinical studies have shown that COX-2 inhibitors celecoxib
and etoricoxib signiﬁcantly extend PSA-free survival after
radical prostatectomy, external radiation, and intermittent
ADT [62–64]. It is noteworthy that the COX-2 status was not
considered in these clinical studies. It is likely that the real
beneﬁt of COX-2 inhibitors in patients with COX-2 positive
PCa is much higher than reported by these studies. Besides
celecoxib and etoricoxib, there is a number of natural COX-2
inhibitors, including vitamin D, curcumin, resveratrol, green
tea, and omega-3 fatty acids (ﬁsh oil) [21].
4.5. Targeting the Stem Cell Pathway. The cancer stem cell
hypothesis predicts that cytotoxic agents (including radia-
tion) may eliminate bulk tumor cells but spare rare cancer
stem cells, which may account for the subsequent dis-
ease relapse after treatment. It has been shown that
the PTEN/PI3K/AKT pathway is critical for the in vitro
maintenance of CD133/CD44 PCa progenitors. In fact,
inhibition of the PTEN/PI3K/AKT pathway by the dual
PI3K/mTOR inhibitor NVP-BEZ235 leads to a decrease
in the population of CD133/CD44 PCa progenitor cells
in vivo. Moreover, the combination of NVP-BEZ235 and
taxotere, which targets the bulk tumor, is signiﬁcantly
more eﬀective in eradicating tumors in a prostate cancer
xenograft model than monotherapy [68]. Another recent
study reports that gamma-tocotrienols (gamma-T3) and
vitamin-E constituents, downregulate the expression of PCa
stem cell markers (CD133/CD44) in androgen-independent
prostate cancer cell lines (PC-3 and DU145), suppress tumor
initiation ability of these cells, and chemosensitizes PC-3 to
taxotere [69]. These preliminary experimental data suggest
that the eﬃcacy of cytotoxic agents in PCa can be enhanced
by targeting the stem cell pathway.
5. Conclusions
RT failure of prostate cancer results from a multifactorial
and heterogeneous disease process including a wide variety
of signaling and eﬀector molecules that often depend on
the genetic and epigenetic background. Most but not all
of pathways and related tissue markers implicated in RT
failure are also relevant for disease progression after surgery
and androgen deprivation, and are detectable by routine
immunohistochemistry in the patient’s PCa tissue long
before the clinical onset of ADT and RT failure. Among
the various biomarkers tested by the RTOG, p16, Ki-67
combined with MDM2, COX-2, and PKA yielded the most
robust data in predicting RT failure. With these markers it10 Prostate Cancer
should be possible to identify patients at high risk to fail RT.
The predictive power of other markers involved in RRPCa,
including AR, EGFR family, VEGF-R, PI3K/Akt/mTOR, and
NE diﬀerentiation, needs to be established. A number of
tissue markers, including the hypersensitive AR, EGFR,
VEGF-R, COX-2, and NF-κB/Stat3 are promising to oﬀer
relevant targets for currently available drugs to enhance
the eﬃcacy of RT. With respect to the potential design of
clinical protocols combining targeted therapy and RT, it is of
paramount importance to ascertain that the target is present
at signiﬁcant levels in the patient’s PCa tissue.
Strategies focusing more on early detection and preven-
tion of RRPCa may be more eﬀective to extend survival
of PCa patients than attempts to improve the outcome of
patients with clinically proven RT failure.
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